Disc Medicine to Present Key Clinical Data at SOHO 2026
Event summary
- Disc Medicine will present initial Phase 2 data for DISC-3405 in polycythemia vera at SOHO 2026.
- Oral presentation of RESTORE-PV trial data scheduled for September 10, 2026.
- Additional myelofibrosis data for DISC-0974 to be presented at the same conference.
- Presentations include both oral and poster formats across multiple sessions.
The big picture
Disc Medicine's presentations at SOHO 2026 highlight its focus on addressing unmet needs in hematologic diseases. The company is positioning itself as a key player in the myeloproliferative neoplasms space, with a portfolio targeting fundamental biological pathways. The strategic significance lies in the potential for DISC-3405 and DISC-0974 to differentiate in a competitive therapeutic landscape.
What we're watching
- Clinical Efficacy
- How the initial safety and efficacy data for DISC-3405 in polycythemia vera will position it against existing treatments.
- Pipeline Progress
- Whether the myelofibrosis data for DISC-0974 will accelerate its development timeline.
- Market Differentiation
- The pace at which Disc Medicine can establish its therapies as first-in-class treatments for myeloproliferative neoplasms.
Related topics